Randomized placebo‐controlled trial of zonisamide in patients with Parkinson's disease

Abstract

AbstractBackgroundWe previously showed that zonisamide significantly improved parkinsonian symptoms by a multicenter, double‐blind clinical trial.AimTo confirm the efficacy of zonisamide on Parkinson's disease, a phase 3, randomized, placebo‐controlled, multicenter, double‐blind trial was carried out in Japan.MethodsParticipants had advanced Parkinson's disease taking L‐dopa with at least one other antiparkinson drug, but were developing a deterioration of response to L‐dopa therapy. The trial consisted of a 2‐week initial phase (single‐blind, with administration of placebo) and a 12‐week treatment phase (double‐blind, with patients randomly assigned to either placebo, or zonisamide 25 or 50 mg/day). Patients were evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS).ResultsA total of 185 patients (mean age 64.8 years; mean duration 7.5 years) were included in the efficacy analysis (placebo, zonisamide 25 mg, 50 mg; 63, 61, 61 patients, respectively). When compared with the placebo group, the UPDRS Part III total score at final assessment (the primary end‐point for efficacy) significantly improved (P = 0.029) in the zonisamide 25 mg group. After 12 weeks of therapy, the UPDRS Part III total score significantly improved in both the zonisamide 25 mg (P = 0.038) and 50 mg groups (P = 0.049), compared with the placebo group. Neither the zonisamide 25 mg nor 50 mg group differed significantly from the placebo group in the incidence of adverse events (P = 0.363 and P = 0.713, respectively).ConclusionThese findings confirmed that zonisamide is well tolerated and efficacious in the treatment of advanced Parkinson's disease.